Category

Pharmaceutical 3744 articles

Beasley Allen has one of the largest and most technologically advanced Mass Torts practices in the country. The Mass Torts division represents numerous people in claims against companies that manufacture and/or market defective pharmaceuticals and/or medical devices. The resources devoted to this division allow the firm to competently and conscientiously handle any group of cases, no matter how large, along with particular catastrophic injury cases.

Our firm was recently involved in one of the greatest victories in Mass Torts history, against drug manufacturer Merck regarding the drug Vioxx. After more than five years of hard-fought and difficult litigation, Merck agreed to pay $4.85 billion, the largest pharmaceutical settlement in U.S. history, to resolve certain Vioxx-related claims involving plaintiffs who suffered a heart attack, including sudden cardiac death, or a stroke.

Statins linked to increased risk of diabetes, diabetes complications, obesity

lipitor

Statin therapy is designed to lower cholesterol levels in order to prevent heart attacks, strokes and cardiovascular death. But a new retrospective cohort study shows that use of statins by healthy adults can increase the risk of type 2 diabetes, diabetes complications and being overweight or obese. Type 2 diabetes is a chronic condition that increases the risk for serious health complications such as heart disease, kidney disease, cancer, blindness, dementia, and amputations to neuropathy. Patients who are diagnosed with diabetes must follow a strict diet and closely monitor their blood sugar levels. Many have to take insulin and other ... Read More

GranuFlo, NaturaLyte bellwether trials scheduled for early 2016

dialysis

More than 1,800 lawsuits claiming dialysis service and supplier Fresenius Medical Care failed to warn doctors or patients that its dialysis products GranuFlo and NaturaLyte could cause serious cardiovascular risks have been consolidated into a multidistrict litigation (MDL). The lawsuits were consolidated under U.S. District Judge Douglas P. Woodlock in the District of Massachusetts. The personal injury and wrongful death lawsuits claim that dialysis giant Fresenius knew the dangers of its dialysis concentrates but neglected to warn health care providers, and also failed to properly train them on how to use the solutions safely. Fresenius manufactures GranuFlo and NaturaLyte, solutions ... Read More

Diabetes drug Victoza being tested as treatment for fatty liver disease

Victoza

Drug maker Novo Nordisk continues to look for new uses for its type 2 diabetes drug Victoza despite serious side effects including pancreatic cancer. The drug company is currently testing Victoza as a treatment for fatty liver disease, a condition for which treatments are limited. Victoza, which contains the active ingredient liraglutide, was shown to resolve fatty liver disease in more than a third of patients who participated in a small phase II study conducted by researchers from University of Birmingham in Britain. Fatty liver disease is the accumulation of fat on the liver that causes inflammation and scarring. It ... Read More

FDA approves new blood thinner to treat atrial fibrillation

blood cells

The Food and Drug Administration (FDA) has approved Daiichi Sankyo’s new blood thinner Savaysa for the prevention of strokes and blood clots in patients with atrial fibrillation not caused by a heart valve, and for the treatment of deep vein thrombosis and pulmonary embolism in patients who have already been treated with an anticlotting medication for five to 10 days. Savaysa, which contains the drug ingredient edoxaban, is the fourth FDA-approved drug in a class of blood thinners known as factor Xa inhibitors. It was approved based on clinical trials that pitted the drug against the long-used warfarin, which belongs to ... Read More

Doctors fighting to ban deadly power morcellation procedures

morcellator

Two Philadelphia-area doctors said they were horrified when the Food and Drug Administration (FDA) issued a safety communication discouraging use of power morcellation for hysterectomies or uterine fibroid removal. The surgical tools had been blamed for spreading undiagnosed uterine cancer and worsening patients’ odds of survival. Drs. Amy Reed and her husband Hooman Noorchashm say the devices should be banned because they are deadly. Power morcellators are surgical tools that are fitted with a long blade that minces entire uteruses or uterine growths inside the abdominal cavity and removes the tissue through a small incision. About 50,000 power morecellation procedures have been ... Read More

Prolonged use of Tylenol during pregnancy linked to birth defects in male babies

sleeping-baby

Tylenol and other medicines containing acetaminophen have long been considered a safe painkiller for pregnant women, but a new study from the University of Edinburth has found that prolonged use of acetaminophen – also known as paracetamol – during pregnancy can drive down testosterone levels in those taking the medicine leading to reproductive disorders in male babies. Researchers gave laboratory mice three doses of acetaminophen every day for a week, and found that the mince given acetaminophen had a 45 percent reduction in testosterone compared to mice who were not given the medicine. Testosterone is produced in the testicles and serves ... Read More

Bleeding side effects, lawsuits may hurt future Xarelto sales

xarelto

Sales of Pfizer’s new blood thinner Eliquis have grown more than fivefold in the previous year to a whopping $774 million, but analysts say Johnson & Johnson and Bayer need not fret just yet about the fate of their blockbuster blood thinner Xarelto. Xarelto has the lion’s share of the anticoagulant market of the new lineup of blood thinners known as Xa inhibitors. Boehringer Ingelheim’s Pradaxa, which hit the market in 2010, was the first in the class of drugs designed to go head-to-head with the long-used warfarin for the prevention of strokes in patients with atrial fibrillation. Pradaxa revenues grew ... Read More

10 things you probably didn’t know about erectile dysfunction

viagra

No one likes to talk about performance issues in the bedroom, but it’s not uncommon. About half of all men between the ages of 40 and 70 experience erectile dysfunction (ED) to some degree. Here are some other ED facts you probably were not aware of: 1. Erectile dysfunction is hard to define but generally it is not considered a medical condition unless a man fails to achieve an erection more than 50 percent of the time. 2. ED can be an early warning sign of other medical issues such as high blood pressure and heart disease. So, if you ... Read More

FDA approves new seasonal schizophrenia drug

johnsonandjohnson

The Food and Drug Administration (FDA) has approved a new version of Johnson & Johnson’s schizophrenia treatment Invega that is administered every three months, making it the longest dosing interval available. The original version of Invega is a tablet administered once daily to treat schizophrenia symptoms in adults and adolescents. It is also used to treat schizoaffective disorder. Another version of the drug, called Invega Sustenna, was introduced in 2009. It is an injectable version that is administered monthly. Invega Trinza is also an injectable drug that is administered just four times a year. “With a dosing interval that can ... Read More

Statin therapy may be unnecessary, cause side effects in elderly

Senior African American couple

People older than 75 who have high cholesterol but no evidence of heart disease may not benefit from statin therapy, according to Sanford cardiologist Dr. Joshua Wynne, who writes the Health Matters column in the Grand Forks Herald. “The problem is that we have very little clinical evidence that statins are beneficial for primary prevention in people … who are over the age of 75. Not only that, but there is some evidence to suggest a higher cholesterol level in the elderly may be associated with less risk of complications,” he writes. Statins, such as the widely prescribed Lipitor, are used ... Read More